# PT-141 Dosage: What the Studies and the Label Document

> PT-141 (bremelanotide) dosage as documented in the studies and the FDA label: the approved 1.75 mg as-needed dose, half-life, and research doses. No personal dosing advice.

The approved labeled dose, the doses used in research, and how long it lasts — described, never prescribed.

## Read this first

This page documents the PT-141 (bremelanotide) dosage that appears in the official label and in published studies. It is a description of the record, not advice — no dose here is a recommendation for any person to take, and we give no instructions.

The short version: the FDA-approved dose, for the one approved use, is 1.75 mg injected under the skin, as needed, no more than once in 24 hours and no more than eight times a month [7]. The peptide is short-acting — it clears with a half-life of roughly 2.7 hours [7]. Research studies have used other doses and routes, including higher doses for non-approved purposes, which we describe below strictly as study facts. If you are looking at PT-141 for any reason, that is a conversation for a licensed clinician, not a website.

## PT-141 dosage

The approved PT-141 dosage is precise and worth stating as the label states it. For acquired, generalized HSDD in premenopausal women, bremelanotide is 1.75 mg given subcutaneously (under the skin) as needed, at least 45 minutes before anticipated sexual activity — with a hard ceiling of one dose per 24 hours and no more than eight doses per month [7].

That ceiling is not arbitrary. It reflects the as-needed design tested in trials and limits repeat exposure linked to side effects like skin darkening [7]. Earlier dose-finding work in women tested 0.75, 1.25, and 1.75 mg by injection before settling on the approved amount [7]. Higher and more frequent doses appear only in non-approval research contexts, described below.

## How long does PT-141 last

PT-141 is short-acting in the body. After a subcutaneous injection, blood levels peak in about 0.5 to 1 hour, and the drug clears with a terminal half-life of roughly 2.7 hours (range 1.9-4.0 hours) per the prescribing information [7]. Early intranasal studies reported a similar half-life of about 1.85-2.09 hours [7].

A short half-life is why the approved use is as-needed rather than daily. Note that "how long it lasts" in the blood is not the same as how long an effect is felt — the 2022 imaging study found desire was raised for up to 24 hours after a single dose, longer than the drug itself lingers, because the action is on brain circuits rather than on a quickly-cleared blood level [5]. The body distributes it into about 25 liters of tissue, clears it at about 6.5 liters per hour, and removes it mostly through the kidneys [7].

## PT-141 dosage for women

For women, the documented PT-141 dosage for women is the approved one: 1.75 mg subcutaneously, as needed, within the once-daily and eight-per-month limits [7]. This is the only dosing with regulatory approval, and only for premenopausal women with HSDD.

The foundational evidence behind a female-specific effect came first from animals: in female rats, PT-141 selectively increased appetitive (desire-driven) sexual behaviors without changing reflexive responses or movement — indicating central melanocortin systems help regulate female sexual desire [2]. The human dose was then defined by the RECONNECT trials at 1.75 mg [3]. No higher "female" dose is approved.

## Doses used in non-approved research

Several studies used PT-141 outside the approved indication, and these are research facts only — not protocols to follow. Early intranasal work in men with erectile dysfunction escalated doses to roughly 7-20 mg, with a statistically significant erectile response above 7 mg; that intranasal route was later discontinued due to inconsistent absorption [1][7].

In a very different setting, two Phase 1 obesity studies in women used subcutaneous doses up to 2.5 mg as often as three times a day for about two weeks — a high-frequency research protocol that reduced body weight (about -1.3 kg vs placebo over 16 days) and caloric intake by acting on appetite-related MC4R [8]. These doses are far above the approved as-needed amount and are not an approved use of PT-141 [7].

---

A plain-English research desk for PT-141 (bremelanotide), reading the newest studies first — the one approved use named, the off-label uses flagged, the modest benefit and the nausea both kept in view; a reading desk, not a clinic, with nothing here dosed or sold.